RxDoctor Payments Data

Brian Kim, MD

Ophthalmology · Burlington, VTNPI 1881655496

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Alimera Sciences, Inc..

$29in general payments, 2019–2025

Across 2 payments — averaging $14.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alimera Sciences, Inc.$29
$373,732in research payments, 2019–2025

Across 60 payments — averaging $6228.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$191K
  • Regeneron$89K
  • Bayer$70K
  • Novartis$18K
  • Kyowa Kirin, Inc.$6K
  • Pfizer$800

What the payments were for

  • Food & beverage$29100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alimera Sciences, Inc.2$29

How this compares

$29 in reported general payments places this provider in the 55th percentile of 35 ophthalmology providers in Vermont.

See all ophthalmology providers in Vermont

Medicare billing

Part B allowed, 2024
$739,935
Medicare patients
548
Services billed
7,409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bromfenac Sodium24$2,774
Prednisolone Acetate22$1,191

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Burlington

See the full list for Vermont

Where these figures come from

Is this you, or does something look wrong? →